Skip Navigation


NDT Advance Access originally published online on January 23, 2006
Nephrology Dialysis Transplantation 2006 21(5):1154-1157; doi:10.1093/ndt/gfk077
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/5/1154    most recent
gfk077v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Névessignsky, M. T.
Right arrow Articles by Ferster, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Névessignsky, M. T.
Right arrow Articles by Ferster, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Haematopoietic stem cell transplantation for severe autoimmune diseases: new perspectives

Michel Toungouz Névessignsky1 and Alina Ferster2

1 Hôpital Erasme and 2 Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Université Libre de Bruxelles, Brussels, Belgium

Correspondence and offprint requests to: M. Toungouz Névessignsky, Department of Immunology-Hematology-Transfusion, Erasme Hospital, 808, route de Lennik, B-1070, Brussels, Belgium. Email: toungouz@ulb.ac.be

Keywords: autoimmune disease; autoimmunity; haematopoietic stem cell transplantation; immune reconstitution; non-myeloablative conditioning

The first 150 words of the full text of this article appear below.



   Introduction
 
Autoimmune diseases affect ~5% of the population. Autoimmunity, inflammation and tissue damage feature in this heterogeneous group of disorders. The potential of haematopoietic stem cell transplantation (HSCT) for the treatment of autoimmune diseases was originally supported by animal experiments (reviewed in van Bekkum [1]) together with occasional remission of autoimmune diseases in patients undergoing HSCT for haematological disorders. Improved safety of both autologous and allogeneic HSCT has allowed the use of such procedures as an experimental treatment for severe autoimmune disease resistant to conventional treatments. One of the first challenges in this context was to bring together haematologists and specialists in many other fields including nephrology, rheumatology, paediatrics, internal medicine and neurology. From now on, data on almost 800 procedures are collated in international databases [2]. Although phase III trials are in progress, the main conclusion that can be drawn from this experience is that HSCT . . . [Full Text of this Article]



   Clinical experience
 


   New perspectives
 
Modulation of immunity
Conditioning regimen and source of haematopoietic stem cells
Immune reconstitution
Regenerative properties of stem cells


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?